← Back to headlines
Merck Stock Valuation Debated Amid Surge and Cancer Vaccine Success
Merck's stock has been a subject of debate regarding its valuation, with analysts questioning if it remains undervalued despite an 80% surge and significant success with its cancer vaccine, following a recent downgrade due to perceived stretched valuation.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
